MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/jcp-2022-208171

Медицинская библиотека · Journal of clinical pathology · 2022

Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.

Perkmann Thomas, Koller Thomas, Perkmann-Nagele Nicole, Ozsvar-Kozma Maria, Eyre David, Matthews Philippa, Bown Abbie, Stoesser Nicole, Breyer Marie-Kathrin, Breyer-Kohansal Robab, Burghuber Otto C, Hartl Slyvia, Aletaha Daniel, Sieghart Daniela, Quehenberger Peter, Marculescu Rodrig, Mucher Patrick, Radakovics Astrid, Klausberger Miriam, Duerkop Mark, Holzer Barba, Hartmann Boris, Strassl Robert, Leitner Gerda, Grebien Florian, Gerner Wilhelm, Grabherr Reingard, Wagner Oswald F, Binder Christoph J, Haslacher Helmuth

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems are often poor, leaving room for false-positive and false-negative results. However, conventional methods were used to increase specificity and decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the 'sensitivity improved two-test' or 'SIT²' algorithm.

METHODS

SIT² involves confirmatory retesting of samples with results falling in a predefined retesting zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT² to single tests and orthogonal testing (OTA) in an Austrian cohort (1117 negative, 64 post-COVID-positive samples) and validated the algorithm in an independent British cohort (976 negatives and 536 positives).

RESULTS

The specificity of SIT² was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT² when compared with single tests or OTA. SIT² allowed correct identification of infected individuals even when a live virus neutralisation assay could not detect antibodies. Compared with single testing or OTA, SIT² significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence.

CONCLUSION

For SARS-CoV-2 serology, SIT² proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.

Для цитирования: Perkmann Thomas, Koller Thomas, Perkmann-Nagele Nicole, Ozsvar-Kozma Maria, Eyre David, Matthews Philippa, Bown Abbie, Stoesser Nicole, Breyer Marie-Kathrin, Breyer-Kohansal Robab, Burghuber Otto C, Hartl Slyvia, Aletaha Daniel, Sieghart Daniela, Quehenberger Peter, Marculescu Rodrig, Mucher Patrick, Radakovics Astrid, Klausberger Miriam, Duerkop Mark, Holzer Barba, Hartmann Boris, Strassl Robert, Leitner Gerda, Grebien Florian, Gerner Wilhelm, Grabherr Reingard, Wagner Oswald F, Binder Christoph J, Haslacher Helmuth. Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.. Journal of clinical pathology. 2022. DOI: 10.1136/jcp-2022-208171.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.